NCT04345913 2026-03-19
Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
National Cancer Institute (NCI)
City of Hope Medical Center
Eisai Inc.
Merck Sharp & Dohme LLC